Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Nat Chem Biol. 2020 Jul 21;16(8):817–825. doi: 10.1038/s41589-020-0596-8

Fig. 3 |. inhibitors with non-overlapping resistance profiles to overcome drug resistance.

Fig. 3 |

a, Schematics show mutant alleles of a target protein with resistance-conferring mutations in the active site (red star, left) and the allosteric site (blue star, right). Schematics of active-site and allosteric-site inhibitors are also shown (cyan and orange, respectively). b, Structural model of Abl1 kinase with inhibitors (sphere representation) bound in the active site (inhibitor in cyan) and the allosteric site (inhibitor in orange). Residues (sphere representation) that can be mutated without loss of protein activity and that confer resistance to inhibitors in the active site (residues in red) or the allosteric site (residues in blue) are shown. PDB: 5MO4. c, Schematic of a target protein with two inhibitors concomitantly bound in the active and allosteric sites.